Effect of Antithymocyte Globulin Source on Outcomes of Bone Marrow Transplantation for Severe Aplastic Anemia  by Antin, Joseph H. et al.
Biol Blood Marrow Transplant 20 (2014) S27eS44ORAL PRESENTATIONS
ALLOGENEIC TRANSPLANTS7
Effect of Antithymocyte Globulin Source on Outcomes of
Bone Marrow Transplantation for Severe Aplastic Anemia
Joseph H. Antin 1, H Joachim Deeg 2, Sandra Korman 3,
Carmem Bonﬁm4, Ryotaro Nakamura 5, Mary M. Horowitz 6,
Daniel Weisdorf 7, Mary Eapen 6, Michael A. Pulsipher 8. 1Dana
Farber Cancer Institute, Boston, MA; 2Clinical Research
Division, Transplantation Biology Program, Fred Hutchinson
Cancer Research Center, Seattle, WA; 3CIBMTR, Medical College
of Wisconsin, Milwaukee, WI; 4Federal University of Parana,
Curitiba, Brazil; 5Hematology/Hematopoietic Cell
Transplantation, City of Hope, Duarte, CA; 6CIBMTR, CIBMTR/
Medical College of Wisconsin, Milwaukee, WI; 7University of
Minnesota, Minneapolis, MN; 8Primary Children’s Medical
Center, University of Utah School of Medicine, Salt Lake City, UT
Both prospective and retrospective studies indicate that in
primary immunosuppressive therapy of severe aplastic ane-
mia (SAA), the use of horse antithymocyte globulin (hATG)
results in higher response rates and better long term out-
comes than rabbit ATG (rATG). However, rATG results inmore
profound and durable immunosuppression than hATG; thus,
the relative beneﬁt might be different when used in the
setting of transplantation conditioning. We previously
showed that bone marrow (BM) is a preferable stem cell
source to PBSC in SAA (Eapen et al Blood. 2011), andwe limited
this analysis to patients given BM.We analyzed the outcomes
of 699 SAA patients registered between 2007 and 2011 with
the CIBMTR who were transplanted from HLA-identical
sibling (MRD) or unrelated donors (URD) and received ATG as
part of the conditioning regimen. Patient characteristics are
shown in Table 1. Patients with URD transplants had a longer
delay fromdiagnosis andweremore likely to receive lowdose
TBI-based conditioning.
The proportions of patients achieving an ANC of 500/mL by 28
days were similar with rATG and hATG: MRD 90 vs. 88%
(p¼0.52), and URD, 86 vs. 90% (p¼0.30). The corresponding
incidence of platelet recovery by 100 days was 94 vs. 95% and
86 vs. 75%, respectively. However, the incidence of grades II-
IV acute GVHD by day 100 was lower with rATG than with
hATG for both MRD: 2 vs. 15% (p¼0.01) and with URDRelated Unrelated
hATG rATG hATG rATG
N 214 233 88 164
Male n (%) 121 (57) 130 (56) 46 (52) 91 (55)
Median age (range) 16 (1e68) 19 (2e65) 20 (1e66) 17 (1e67)
Diagnosis to BMT
<6 months 169 (79) 163 (70) 12 (14) 31 (19)
6 e 12 months 22 (10) 42 (18) 39 (44) 48 (29)
 1 year 23 (11) 28 (12) 37 (42) 84 (51)
Conditioning
Cy/ATG 198 (93) 168 (72) 8 (9) 2 (1)
Cy/ATG/Flu 16 (7) 65 (28) 9 (10) 45 (27)
Cy/ATG/TBI (3-8Gy) __ __ 4 (5) 5 (3)
Cy/ATG/TBI (2Gy) __ __ 38 (43) 30 (18)
Cy/ATG/Flu/TBI (2Gy) __ __ 28 (32) 70 (43)
ATG /other __ __ 1 (1) 12 (7)
GVHD Prophylaxis, N (%)
Tacrolimus-containing 63 (29) 49 (21) 36 (41) 58 (35)
Cyclosporine-containing 151 (71) 184 (79) 52 (59) 106 (65)transplants 23 vs. 43% (p¼0.06). Chronic GVHD was lower
with rATG at 1-year in MRD 5 vs. 12% (p¼0.02), but both
products gave similar risks of cGVHD in URD 16 vs. 14%
(p¼0.63). Overall cGVHD risk was low, and there was no
signiﬁcant difference at 3 years: MRD 9 vs. 13% (p¼0.25) and
URD 19 vs. 21% (p¼0.75). Survival at 100 days was better with
hATG in MRD transplants 97 vs. 94% (p¼0.05) but not URD
transplants 88 vs. 83% (p¼0.25). However,1 year survival was
similar with both ATG formulations in MRD 92 vs. 92%
(p¼.92) and in URD 80 vs. 71% (p¼0.16), although in both
settings rATG was slightly superior. Thus, rATG use leads to
signiﬁcantly less aGVHD in both MRD and URD trans-
plantation. While an advantage in survival was noted in URD
receiving rATG, at the power of this study statistical signiﬁ-
cance was not achieved.8
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An elevated serum ferritin before allogeneic stem cell
transplantation (HSCT) is an adverse prognostic factor for
overall survival (OS) and non-relapse mortality (NRM); but
because ferritin is an imperfect surrogate of iron stores, the
exact prognostic role of iron overload remains unproven.
Four prospective studies using liverMRI to estimate liver iron
content (LIC) have examined the impact of elevated LIC on
HSCT outcome (Armand et al. Am J Hematol. 2012;87(6):569,
Wermke et al. Clin Cancer Res. 2012;18(23):6460, Virtanen et
al. Eur J Haematol. 2013;91(1):85, Trottier et al. Blood.
2013;122(9):1678), but have reached different conclusions
on the prognostic relevance of LIC in HSCT. We therefore
conducted an individual patient data meta-analysis of those
4 studies, using a random effects model. The outcomes of
interest were OS and NRM. 276 patients were included in this
analysis. The median serum ferritin pre-HSCT was 1523
(range, 20-8,878) ng/ml, and the median LIC was 5.0 (range,
0.3-25.4) mg/gdw. 38% of patients received a myeloablative
conditioning regimen. With a median follow-up of 22
months for survivors, the estimated 2-year OSwas 62% (95CI,
55-68), and the NRM was 25% (95CI, 20-31). The pooled
hazard ratio (HR) for mortality associated with a pre-HSCT
LIC>7 mg/gdw (the primary endpoint) was 1.39 (95CI, 0.85-
2.27), p¼0.18 (Figure 1A). The pooled hazard ratio (HR) for
mortality associated with a pre-HSCT ferritin >1000 ng/ml
was 1.68 (95CI, 1.03-2.73), p¼0.036 (Figure 1B). There was no
signiﬁcant association between LIC>5 mg/gdw and OS, or
between ferritin>2500 ng/ml and OS. The signiﬁcant
